Printer Friendly

RESULTS OF IMMUNOGEN'S PHASE I CLINICAL TRIAL USING ONCOLYSIN B SUBSEQUENT TO BONE MARROW TRANSPLANTATION PUBLISHED IN BLOOD

 CAMBRIDGE, Mass., May 6 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the publication of Phase I clinical trial results of its lead product, Oncolysin B, in the major medical journal, Blood (Vol. 81, No. 9: pp. 2263-2271, 1993). The trial established the drug's safety profile in patients with B-cell lymphoma who are in remission subsequent to autologous bone marrow transplantation (ABMT). Results show that the drug can be administered safely to this patient population with tolerable, transient side-effects. Clinical investigators also measured the extension of patients' disease-free survival following ABMT and treatment with Oncolysin B. To date, 10 of the 12 patients treated in the trial, or 83 percent, remain in complete remission with a median time from transplant of 27 months. Historically, only 30-40 percent of patients remain in remission two years after ABMT.
 "This early clinical study suggests that Oncolysin B may be very effective in the treatment of lymphoma patients in remission, to extend their period of disease-free survival," explains Mitchel Sayare, chairman and chief executive officer. "Because our drug acts through a different mechanism than the conventional agents used to induce remission, we believe it can eliminate the residual tumor cells that eventually cause relapse in a majority of cases.
 "Based on data from this study and a subsequent study in this setting," adds Sayare, "ImmunoGen recently began a randomized, controlled, multicenter Phase III clinical trial in patients in remission subsequent to ABMT. It is designed to demonstrate the drug's effectiveness and to secure regulatory approval for marketing. We believe this use of Oncolysin B -- to extend disease-free survival of patients with residual disease -- will fill a major, unmet medical need." There are approximately 70,000 new cases of B-cell cancer in the United States each year treatable with Oncolysin B.
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first-generation products, the Oncolysins, are each comprised of a highly specific monoclonal antibody, linked to blocked ricin, a proprietary derivative of the powerful plant toxin, ricin.
 -0- 5/6/93
 /CONTACT: Mark Ratner, director of external communications of ImmunoGen, 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU:

DD -- NE004 -- 5258 05/06/93 09:16 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1993
Words:386
Previous Article:DISNEY-MGM STUDIOS THEME PARK WELCOMES HOLLYWOOD'S BEST FOR ACADEMY OF TELEVISION ARTS & SCIENCES' HALL OF FAME CEREMONIES
Next Article:FILENE'S BASEMENT REPORTS APRIL SALES
Topics:


Related Articles
IMMUNOGEN'S BLOCKED RICIN TECHNOLOGY INCREASES POTENCY OF CANCER THERAPEUTICS 1,000-FOLD: RESEARCHERS REPORT DATA IN CANCER RESEARCH
IMMUNOGEN'S BLOCKED RICIN TECHNOLOGY INCREASES POTENCY OF CANCER THERAPEUTICS 1,000-FOLD: RESEARCHERS REPORT DATA IN CANCER RESEARCH
IMMUNOGEN'S PHASE I CLINICAL TRIALS DATA WITH ONCOLYSIN B PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY MEETING
IMMUNOGEN ANNOUNCES SECOND QUARTER FISCAL YEAR 1992 RESULTS
APPLIED IMMUNE SCIENCES RECEIVES FDA APPROVAL TO BEGIN BREAST CANCER TRIALS
CLINICAL TRIALS OF IMMUNOGEN'S ONCOLYSIN B EXPANDED; NCI TO BEGIN MULTICENTER STUDY IN CHILDREN WITH LEUKEMIA AND LYMPHOMA
CELLPRO COMPLETES PATIENT ENROLLMENT FOR PHASE III LICENSING TRIAL OF CEPRATE SC STEM CELL SEPARATION SYSTEM
ONCOLYSIN(R) CD6, IMMUNOGEN'S FOURTH PRODUCT, ENTERS PHASE I HUMAN CLINICAL TRIALS
IMMUNOGEN OPENS A NEW MANUFACTURING FACILITY IN CANTON, MASSACHUSETTS
IMMUNOGEN RECEIVES U.S. PATENT ON USE OF ITS CYTOTOXIC AGENT, DC1, IN IMMUNOCONJUGATES

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters